INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
ID: 360655Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$100K - $0

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the INCLUDE Project, specifically for Clinical Trials Phased Awards aimed at advancing research on Down syndrome. This grant program encourages Exploratory/Developmental Phased Innovation (R61/R33) applications to develop clinical trials addressing critical health conditions associated with Down syndrome, with a focus on milestone-driven research. The total funding available for this initiative is approximately $3 million, with an expected four awards, and applications may request a minimum of $100,000. Interested applicants should note that the project period can extend up to five years, with the R61 phase supporting preliminary studies for up to two years, followed by a potential R33 phase for clinical trial support. For further inquiries, applicants can contact Laurie Ryan, PhD, at 301-496-9350 or via email at ryanl@nih.gov. The application deadline is set for February 19, 2026, with awards anticipated to be announced by September 1, 2026.

    Point(s) of Contact
    Files
    No associated files provided.
    Similar Opportunities
    INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE Project: Transformative Research Awards for Down syndrome, aimed at advancing innovative research to improve health and quality of life for individuals with Down syndrome. This funding opportunity invites applications for groundbreaking research that can establish new scientific paradigms or develop transformative technologies related to Down syndrome and its co-occurring conditions, with no preliminary data required. The program has an estimated total funding of $3 million, with individual awards ranging from $250,000 to $500,000, and is expected to support approximately four projects. Interested applicants can reach out to Dr. Charlene Schramm at schrammc@nih.gov or by phone at 301-402-3793, with applications due by February 19, 2026, and anticipated awards announced by September 1, 2026.
    INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome, aimed at enhancing health and quality of life for individuals with Down syndrome. This funding opportunity invites researchers to propose innovative exploratory and developmental projects that address critical needs identified in the INCLUDE Project objectives, potentially leading to breakthroughs in biomedical, behavioral, or clinical research. The total estimated program funding is $1 million, with individual awards ranging from $50,000 to $200,000, and the application process is open to a diverse range of eligible applicants, including tribal governments and community-based organizations. Interested parties should contact Dr. Melissa Parisi at 301-728-1861 or via email at parisima@mail.nih.gov for further information, with applications due by February 19, 2026, and awards expected to be announced by September 1, 2026.
    Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) aimed at developing animal models and biological materials for Down syndrome (DS) research. This initiative, part of the INCLUDE Project, seeks to enhance understanding of co-occurring conditions associated with DS and improve health outcomes for affected individuals through innovative research. Eligible applicants, including higher education institutions, nonprofits, and local governments, can request up to $200,000 for a single year, with a total project period not exceeding two years. Interested parties should submit their applications by January 7, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Animal Models and Related Biological Materials for Down Syndrome Research" under the INCLUDE Project. This initiative aims to support exploratory and innovative research focused on developing and characterizing animal models and biological materials that are essential for Down syndrome (DS) studies, with an emphasis on improving access to these resources and enhancing the rigor of preclinical research. The funding opportunity is particularly significant as it addresses critical gaps in DS research, encouraging projects that utilize advanced technologies such as artificial intelligence and machine learning. Eligible applicants can receive up to $200,000 for a two-year project period, with applications due in March, June, October, and February each year, and the announcement set to expire on January 8, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Predoctoral to Postdoctoral Fellow Transition Award (F99/K00), aimed at recruiting exceptional graduate students for Down syndrome-related research. This opportunity invites interdisciplinary applications from diverse fields such as genetics, biochemistry, data science, imaging, engineering, and neurobiology, providing two phases of support: the F99 phase for 1-2 years of dissertation research, followed by the K00 phase for up to 4 years of mentored postdoctoral training. The NIH plans to commit $1.5 million in FY2025 for up to 20 awards, contingent on the quality of applications, with a submission deadline of July 1, 2026. Interested applicants are encouraged to contact the NIH Grants Information at grantsinfo@nih.gov for further inquiries and to review the full announcement at NIH Grants.
    Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed)." This initiative invites applications to utilize existing biospecimens to generate integrated genomic and multi-omics data aimed at uncovering the molecular mechanisms associated with health conditions related to Down syndrome. The program emphasizes the importance of including cohorts from underrepresented racial and ethnic groups and does not provide direct funding; instead, it facilitates access to sequencing resources for various genomic profiling techniques. Interested applicants should note that the earliest submission date is February 13, 2024, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-081.html.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)" aimed at supporting clinical projects that enhance readiness for clinical trials in rare diseases. This initiative seeks applications that focus on developing and testing biomarkers and clinical outcome measures, as well as defining the characteristics of rare diseases to facilitate the design of future clinical trials. The program is particularly important for addressing the needs of rare diseases affecting fewer than 200,000 individuals in the U.S., with a maximum budget of $275,000 for direct costs over a project period of up to two years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for July 20, 2028.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.